Renal functional response to dopamine during and after arteriography in patients with chronic renal insufficiency
- PMID: 2202010
- DOI: 10.1148/radiology.176.3.2202010
Renal functional response to dopamine during and after arteriography in patients with chronic renal insufficiency
Abstract
The potential renal vasodilatory effect of dopamine in improving renal function after arteriography was studied. Sixty patients with preexisting renal insufficiency were prospectively randomized into two groups. Patients in the treated group (n = 30) received an infusion of dopamine for 12 hours starting at the beginning of arteriography. Patients who received placebo infusion with arteriography (n = 30) served as controls. The study was conducted in two different time intervals. In the first interval, serum creatinine levels and 12-hour creatinine clearance values were obtained before and immediately after arteriography in 12 patients in the dopamine group and 13 patients in the control group. In the second interval, the same variables were measured before arteriography and for 3 consecutive days after arteriography in 18 patients in the dopamine group and 17 patients in the control group. Serum creatinine levels became significantly elevated in the control group on the 1st day and remained so on the 3rd day after arteriography, whereas the dopamine group did not show significant elevation of these levels. Creatinine clearance decreased in the control group on the 1st day, but this deterioration was not sustained on the 3rd day. In the dopamine group, there was no deterioration in creatinine clearance on either day, and mean effective renal plasma flow during and after arteriography was greater.
Similar articles
-
Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency.Am Surg. 1998 May;64(5):432-6. Am Surg. 1998. PMID: 9585778 Clinical Trial.
-
Effect of postoperative low-dose dopamine on renal function after elective major vascular surgery.Ann Intern Med. 1994 May 1;120(9):744-7. doi: 10.7326/0003-4819-120-9-199405010-00004. Ann Intern Med. 1994. PMID: 8147547 Clinical Trial.
-
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.JAMA. 2003 Nov 5;290(17):2284-91. doi: 10.1001/jama.290.17.2284. JAMA. 2003. PMID: 14600187 Clinical Trial.
-
Low-dose dopamine: a systematic review.Intensive Care Med. 2002 Jul;28(7):877-83. doi: 10.1007/s00134-002-1346-y. Epub 2002 May 31. Intensive Care Med. 2002. PMID: 12122525 Review.
-
Pro: dopamine and renal preservation.J Cardiothorac Vasc Anesth. 1995 Jun;9(3):333-4. doi: 10.1016/s1053-0770(05)80331-3. J Cardiothorac Vasc Anesth. 1995. PMID: 7669969 Review. No abstract available.
Cited by
-
[What is reliable in prevention of contrast medium-induced nephropathy?].Med Klin (Munich). 1997 Jun 15;92(6):329-34. doi: 10.1007/BF03044773. Med Klin (Munich). 1997. PMID: 9297064 Review. German.
-
Insights into cisplatin-induced neurotoxicity and mitochondrial dysfunction in Caenorhabditis elegans.Dis Model Mech. 2022 Mar 1;15(3):dmm049161. doi: 10.1242/dmm.049161. Epub 2022 Mar 31. Dis Model Mech. 2022. PMID: 35107130 Free PMC article.
-
The identification of dual protective agents against cisplatin-induced oto- and nephrotoxicity using the zebrafish model.Elife. 2020 Jul 28;9:e56235. doi: 10.7554/eLife.56235. Elife. 2020. PMID: 32720645 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
